From its base in Hong Kong, Akeso Inc. has crossed a threshold that few biopharmaceutical companies reach quietly: the moment when years of scientific ambition begin to register as commercial reality. Reporting record drug sales of nearly 1.8 billion yuan in the first half of 2026, the company stands at the intersection of immunotherapy innovation and global oncology need, with two first-in-class bispecific antibodies now challenging established treatment standards across multiple cancers. The deeper story is not merely one of revenue, but of a deliberate architecture — a pipeline designed to